The role of the E6-p53 interaction in the molecular pathogenesis of HPV

[1]  Miranda Thomas,et al.  Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. , 1999, The Journal of general virology.

[2]  L. Wiesmüller,et al.  Different Regulation of the p53 Core Domain Activities 3′-to-5′ Exonuclease and Sequence-Specific DNA Binding , 1999, Molecular and Cellular Biology.

[3]  J. Roth,et al.  Adenovirus Type 5 E4orf3 Protein Relieves p53 Inhibition by E1B-55-Kilodalton Protein , 1999, Journal of Virology.

[4]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[5]  L. Chow,et al.  Human Papillomavirus DNA Replication , 1999, The Journal of Biological Chemistry.

[6]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[7]  D. Wazer,et al.  The E6 Oncoproteins of High-Risk Papillomaviruses Bind to a Novel Putative GAP Protein, E6TP1, and Target It for Degradation , 1999, Molecular and Cellular Biology.

[8]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[9]  L. Banks,et al.  E3-Ubiquitin Ligase/E6-AP Links Multicopy Maintenance Protein 7 to the Ubiquitination Pathway by a Novel Motif, the L2G Box* , 1998, The Journal of Biological Chemistry.

[10]  Miranda Thomas,et al.  Inhibition of Bak-induced apoptosis by HPV-18 E6 , 1998, Oncogene.

[11]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[12]  I. Jacobs,et al.  p53 codon 72 polymorphism and risk of cervical cancer in UK , 1998, The Lancet.

[13]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[14]  M. Stanley,et al.  A C-Terminal Helicase Domain of the Human Papillomavirus E1 Protein Binds E2 and the DNA Polymerase α-Primase p68 Subunit , 1998, Journal of Virology.

[15]  L. Chin,et al.  The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.

[16]  A. Kristjuhan,et al.  p53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication , 1998, Journal of Virology.

[17]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[18]  Daniela Gardiol,et al.  Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6. , 1998, The Journal of general virology.

[19]  Peng Huang.  Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein , 1998, Oncogene.

[20]  A. Ciechanover,et al.  Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Scheffner,et al.  The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. , 1998, European journal of biochemistry.

[23]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[24]  M. Scheffner,et al.  Characterization of Human hect Domain Family Members and Their Interaction with UbcH5 and UbcH7* , 1998, The Journal of Biological Chemistry.

[25]  M. Eilers,et al.  Control of cell proliferation by Myc. , 1998, Trends in cell biology.

[26]  V. Golubovskaya,et al.  Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein , 1998, Oncogene.

[27]  S. Waddell,et al.  Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast , 1998, Oncogene.

[28]  M. Yutsudo,et al.  Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6 , 1998, Molecular carcinogenesis.

[29]  E. Fortunato,et al.  p53 and RPA Are Sequestered in Viral Replication Centers in the Nuclei of Cells Infected with Human Cytomegalovirus , 1998, Journal of Virology.

[30]  P. Muganda,et al.  The human cytomegalovirus IE2 86 kDa protein elevates p53 levels and transactivates the p53 promoter in human fibroblasts. , 1998, Cellular and molecular biology.

[31]  E. Wilander,et al.  Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. , 1998, Cancer research.

[32]  L. Laimins,et al.  Human Papillomavirus Oncoproteins E6 and E7 Independently Abrogate the Mitotic Spindle Checkpoint , 1998, Journal of Virology.

[33]  R. Schlegel,et al.  The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints , 1997, Oncogene.

[34]  T. Iftner,et al.  A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. , 1997, Virology.

[35]  C. Moyret-Lalle,et al.  Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function , 1997, Oncogene.

[36]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[37]  S. Napthine,et al.  Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. , 1997, Virology.

[38]  E. de Villiers,et al.  Prevailing papillomavirus types in non‐melanoma carcinomas of the skin in renal allograft recipients , 1997, International journal of cancer.

[39]  M Fujita,et al.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[41]  D. Pim,et al.  Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth , 1997, Oncogene.

[42]  S. S. Lee,et al.  Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Blow,et al.  The RLF‐M component of the replication licensing system forms complexes containing all six MCM/P1 polypeptides , 1997, The EMBO journal.

[44]  R. Schlegel,et al.  The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length* , 1997, The Journal of Biological Chemistry.

[45]  P. Howley,et al.  The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Muramatsu,et al.  ERC-55, a binding protein for the papilloma virus E6 oncoprotein, specifically interacts with vitamin D receptor among nuclear receptors. , 1997, Biochemical and biophysical research communications.

[47]  L. Zhong,et al.  Assembly of complete, functionally active herpes simplex virus DNA replication compartments and recruitment of associated viral and cellular proteins in transient cotransfection assays , 1997, Journal of virology.

[48]  G. Wahl,et al.  DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. , 1997, Cancer research.

[49]  C. Wheeler,et al.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective , 1997, Journal of virology.

[50]  P. Beer-Romero,et al.  Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells , 1997, Oncogene.

[51]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  F. Hoppe-Seyler,et al.  Cellular responses of HPV‐positive cancer cells to genotoxic anti‐cancer agents: Repression of E6/E7‐oncogene expression and induction of apoptosis , 1996, International journal of cancer.

[53]  J. Schiller,et al.  Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. , 1996, Cancer research.

[54]  H. Stöppler,et al.  Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation , 1996, Journal of virology.

[55]  P. Bryant,et al.  Dlg protein is required for junction structure, cell polarity, and proliferation control in Drosophila epithelia , 1996, The Journal of cell biology.

[56]  A. Stenlund,et al.  The initiator protein E1 binds to the bovine papillomavirus origin of replication as a trimeric ring‐like structure. , 1996, The EMBO journal.

[57]  X. Li,et al.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation , 1996, Journal of virology.

[58]  A. Jackman,et al.  The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. , 1996, Virus research.

[59]  R. Schlegel,et al.  Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16 , 1996, Journal of virology.

[60]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[61]  T. Crook,et al.  Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. , 1996, Virology.

[62]  T. Tlsty,et al.  Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation , 1996, Journal of virology.

[63]  A. Stenlund,et al.  Co‐operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. , 1995, The EMBO journal.

[64]  C. Prives,et al.  p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner , 1995, Molecular and cellular biology.

[65]  S. Stacey,et al.  Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame , 1995, Journal of virology.

[66]  T. R. Broker,et al.  Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. , 1995, Genes & development.

[67]  Y. Taketani,et al.  Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. , 1995, Virology.

[68]  H. Pan,et al.  Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. , 1995, Genes & development.

[69]  E. Androphy,et al.  Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. , 1995, Science.

[70]  L. Cox,et al.  A direct effect of activated human p53 on nuclear DNA replication. , 1995, The EMBO journal.

[71]  B. Rose,et al.  Associations between oncogenic human papillomaviruses and local invasive patterns in cervical cancer. , 1995, Gynecologic oncology.

[72]  L. Donehower,et al.  Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. , 1995, Cancer research.

[73]  M. Scheffner,et al.  A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  K. Vousden,et al.  Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.

[75]  P. Muganda,et al.  Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts , 1994, Journal of virology.

[76]  C. Peyton,et al.  Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. , 1994, The Journal of infectious diseases.

[77]  T. Iftner,et al.  Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1 , 1994, Journal of virology.

[78]  M. Yutsudo,et al.  Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts , 1994, Journal of medical virology.

[79]  D. Pim,et al.  Characterization of the human papillomavirus E2 protein: evidence of trans‐activation and trans‐repression in cervical keratinocytes. , 1994, The EMBO journal.

[80]  D. Branton,et al.  Cloning and characterization of hdlg: the human homologue of the Drosophila discs large tumor suppressor binds to protein 4.1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[81]  G. Demers,et al.  The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest , 1994, Journal of virology.

[82]  M. Lechner,et al.  Inhibition of p53 DNA binding by human papillomavirus E6 proteins , 1994, Journal of virology.

[83]  S. Ishii,et al.  Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin , 1994, Journal of virology.

[84]  T. Kanda,et al.  Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site , 1994, Molecular and cellular biology.

[85]  Stephen J. Elledge,et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.

[86]  T. Tlsty,et al.  Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. , 1994, Genes & development.

[87]  Hongtao Yu,et al.  Structural basis for the binding of proline-rich peptides to SH3 domains , 1994, Cell.

[88]  D. McCance,et al.  Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin , 1993, Journal of virology.

[89]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[90]  J. Blow,et al.  Preventing re-replication of DNA in a single cell cycle: evidence for a replication licensing factor , 1993, The Journal of cell biology.

[91]  M. Scheffner,et al.  Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins , 1993, Molecular and cellular biology.

[92]  Kathleen R. Cho,et al.  Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Scheffner,et al.  Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53 , 1993, Molecular and cellular biology.

[94]  J. C. Johnson,et al.  Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer. , 1992, Gynecologic oncology.

[95]  P. Howley,et al.  The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein. , 1992, The EMBO journal.

[96]  M. Remm,et al.  The E2 binding sites determine the efficiency of replication for the origin of human papillomavirus type 18. , 1992, Nucleic acids research.

[97]  T. Crook,et al.  Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. , 1992, The EMBO journal.

[98]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[99]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[100]  G. Matlashewski,et al.  Molecular analysis of different allelic variants of wild-type human p53. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[101]  J. Minna,et al.  Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins , 1992, Journal of virology.

[102]  T. Crook,et al.  Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription. , 1992, The EMBO journal.

[103]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[104]  H. Sato,et al.  Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. , 1991, Virology.

[105]  V. Band,et al.  Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells , 1991, Journal of virology.

[106]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[107]  K. Vousden,et al.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.

[108]  G. Orth,et al.  Genetic heterogeneity among human papillomaviruses (HPV) associated with epidermodysplasia verruciformis: evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. , 1991, Virology.

[109]  D. Lowy,et al.  The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture , 1991, Journal of virology.

[110]  H. Hausen.  Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .

[111]  K. Münger,et al.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[112]  B. Vogelstein,et al.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication , 1991, Cell.

[113]  D. Lane,et al.  Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells , 1991, Nature.

[114]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[115]  M. Stanley,et al.  Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. , 1990, Virology.

[116]  R. Stein,et al.  Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[117]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[118]  D. Lowy,et al.  Papillomavirus polypeptides E6 and E7 are zinc-binding proteins , 1989, Journal of virology.

[119]  H. Prokoph,et al.  Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms , 1989, Journal of virology.

[120]  T. Iftner,et al.  Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication , 1988, Journal of virology.

[121]  A. Schneider-Gädicke,et al.  Identification of the human papillomavirus type 18 E6 and E6 proteins in nuclear protein fractions from human cervical carcinoma cells grown in the nude mouse or in vitro. , 1988, Cancer research.

[122]  D. McGeoch,et al.  Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis , 1988, Journal of virology.

[123]  J. Jenkins,et al.  Mouse p53 inhibits SV40 origin-dependent DNA replication , 1987, Nature.

[124]  D. Lane,et al.  p53 and DNA polymerase α compete for binding to SV40 T antigen , 1987, Nature.

[125]  E. Androphy,et al.  Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. , 1987, The Journal of general virology.

[126]  D. Lowy,et al.  Identification of the HPV‐16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. , 1987, The EMBO journal.

[127]  S. Cole,et al.  Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. , 1987, Journal of molecular biology.

[128]  D. Pim,et al.  Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.

[129]  A. Schneider-Gädicke,et al.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. , 1986, The EMBO journal.

[130]  F. Wettstein,et al.  Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[131]  D. Pim,et al.  Analysis of human p53 proteins and mRNA levels in normal and transformed cells. , 1986, European journal of biochemistry.

[132]  Wolfgang Mayer,et al.  Structure and transcription of human papillomavirus sequences in cervical carcinoma cells , 1985, Nature.

[133]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[134]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[135]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[136]  L. Wiesmüller,et al.  The dual role model for p53 in maintaining genomic integrity , 1999, Cellular and Molecular Life Sciences CMLS.

[137]  A. Ciechanover,et al.  The ubiquitin system for protein degradation. , 1992, Annual review of biochemistry.

[138]  H. Sato,et al.  Expression of human papillomavirus type 16 E7 gene induces DNA synthesis of rat 3Y1 cells. , 1989, Virology.

[139]  H. Hausen,et al.  The Role of Papillomaviruses in Human Anogenital Cancer , 1987 .

[140]  Rougui Zineb,et al.  Distinct, tissue-specific regulation of vitamin D receptor in the intestine, kidney, and skin by dietary calcium and vitamin D. , 1998, Endocrinology.